CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial

CalciMedica, Inc.

2023-Q3 EPS reported -$7.43

Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.
Auxora Phase 1/2 CRSPA in AIPT: 53% reduction in hospital days, 40% ICU days, eliminated TPN vs 27 days historical control. Data at ASH Dec 2023.
Phase 2b CARPO in acute pancreatitis with SIRS enrolling internationally; topline data H1 2024.
Preparing IND for Auxora in acute kidney injury; Phase 2 could start H1 2024 subject to funding.
Operating expenses $4.8M Q3; nine-month net loss $30.2M includes one-time merger charges.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CalciMedica, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $4.6 million, or $0.82 per share (basic and diluted), EPS $0.82 per share (basic and diluted).

Period: the third quarter ended September 30, 2023
Net income: Net loss was $4.6 million, or $0.82 per share (basic and diluted)
EPS: $0.82 per share (basic and diluted)
Result: reported results

Exact text from the filing

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.